Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study (Q33416122)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andrzej Deptała

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

object named as

Timothy Iveson

1

1 reference

ORCID Public Data File 2021

author name string

Ross C Donehower

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Irina Davidenko

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sergey Tjulandin

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mark Harrison

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Somanath Nirni

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Kuntegowdanahalli Lakshmaiah

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Anne Thomas

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Yizhou Jiang

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Min Zhu

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Rui Tang

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Abraham Anderson

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sarita Dubey

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Kelly S Oliner

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Elwyn Loh

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

22 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1007-1018

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting MET in cancer: rationale and progress

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

MET Expression and Amplification in Patients with Localized Gastric Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Increase in the circulating level of hepatocyte growth factor in gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Prospective Phase II Study to Compare the Combination Chemotherapy Regimen Epirubicin, Cisplatin, and 5-Fluorouracil With Epirubicin, Cisplatin, and Capecitabine in Patients With Advanced or Metastatic Gastric Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970023-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70023-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24965569%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33416122&oldid=1622978581"